Clinical Trials /

A Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

NCT04195750

Description:

The primary objective of this study is to compare MK-6482 to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that MK-6482 is superior to everolimus with respect to PFS and OS.

Related Conditions:
  • Clear Cell Renal Cell Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 3

Trial Eligibility

Document

Title

  • Brief Title: A Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
  • Official Title: An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

Clinical Trial IDs

  • ORG STUDY ID: 6482-005
  • SECONDARY ID: 2019-003444-72
  • SECONDARY ID: MK-6482
  • NCT ID: NCT04195750

Conditions

  • Carcinoma, Renal Cell

Interventions

DrugSynonymsArms
MK-6482MK-6482
EverolimusAfinitor, Afinitor DISPERZ, ZortressEverolimus

Purpose

The primary objective of this study is to compare MK-6482 to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that MK-6482 is superior to everolimus with respect to PFS and OS.

Trial Arms

NameTypeDescriptionInterventions
MK-6482ExperimentalParticipants receive 120 mg of MK-6482 orally once daily (QD) for up to ~20 weeks
  • MK-6482
EverolimusActive ComparatorParticipants receive 10 mg of Everolimus orally once daily (QD) for up to ~20 weeks
  • Everolimus

Eligibility Criteria

        Inclusion Criteria:

          -  Has unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC)

          -  Has received systemic treatment for locally advanced or metastatic RCC with a
             Programmed cell death 1 ligand 1 (PD-1/L1) checkpoint inhibitor (at least 2 doses of a
             PD-1/L1 checkpoint inhibitor) and a vascular endothelial growth factor (VEGF) targeted
             therapy (including tyrosine kinase inhibitors or monoclonal antibodies) as
             monotherapy, or in combination.

          -  Has received no more than 3 prior systemic regimens for locally advanced or metastatic
             RCC.

          -  A male participant must agree to use contraception during the treatment period and for
             at least 95 days.

          -  A female participant is eligible to participate if she is not pregnant, not
             breastfeeding, and at least 1 of the following conditions applies: Not a (woman of
             childbearing potential) WOCBP OR A WOCBP who agrees to follow the contraceptive
             guidance during the treatment period and for at least 95 days after the last dose of
             study intervention.

          -  The participant (or legally acceptable representative if applicable) provides written
             informed consent for the study.

          -  Has adequate organ function

        Exclusion Criteria:

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 3 years. (Participants with basal cell carcinoma of the skin, squamous
             cell carcinoma of the skin, or carcinoma in situ [e.g., breast carcinoma, cervical
             cancer in situ] that have undergone potentially curative therapy are not excluded.)

          -  Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.
             (Participants with previously treated brain metastases may participate provided they
             are radiologically stable for at least 4 weeks (28 days) by repeat imaging.)

          -  Has clinically significant cardiac disease, including unstable angina, acute
             myocardial infarction within 6 months from Day 1 of study drug administration, or New
             York Heart Association Class III or IV congestive heart failure. (Medically controlled
             arrhythmia stable on medication is permitted.)

          -  Has poorly controlled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg
             and/or diastolic blood pressure (DBP) ≥90 mm Hg.

          -  Has moderate to severe hepatic impairment (Child-Pugh B or C).

          -  Has a known psychiatric or substance abuse disorder that would interfere with
             cooperation with the requirements of the study.

          -  Is unable to swallow orally administered medication or has a gastrointestinal disorder
             affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption).

          -  Has known hypersensitivity or allergy to the active pharmaceutical ingredient or any
             component of the study intervention (MK-6482 or everolimus) formulations.

          -  Has received prior treatment with MK-6482 or another hypoxia inducible factor 2α
             (HIF-2α inhibitor).

          -  Has received prior treatment with everolimus or any other specific or selective target
             of rapamycin complex 1 (TORC1)/ phosphatidylinositol 3-kinase (PI3K)/ protein kinase B
             (AKT) inhibitor (e.g., temsirolimus) in the advanced disease setting.

          -  Has received any type of systemic anticancer antibody (including investigational
             antibody) within 4 weeks before randomization.

          -  Has received prior radiotherapy within 2 weeks prior to first dose of study
             intervention.

          -  Has had major surgery within 3 weeks prior to first dose of study intervention.

          -  Has received a live vaccine within 30 days prior to the first dose of study drug.
             Examples of live vaccines include, but are not limited to, the following: measles,
             mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
             Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
             are generally killed virus vaccines and are allowed; however, intranasal influenza
             vaccines are live attenuated vaccines and are not allowed.

          -  Is currently receiving either strong (e.g., itraconazole, telithromycin,
             clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir,
             saquinavir, nelfinavir, boceprevir, telaprevir) or moderate (e.g., ciprofloxacin,
             erythromycin, diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450 3A4
             (CYP3A4) that cannot be discontinued for the duration of the study.

          -  Is currently receiving either strong (phenobarbital, enzalutamide, phenytoin,
             rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or
             moderate (e.g., bosentan, efavirenz, modafinil) inducers of CYP3A4 that cannot be
             discontinued for the duration of the study.

          -  Is currently participating in a study of an investigational agent or is currently
             using an investigational device.

          -  Has an active infection requiring systemic therapy.

          -  Has active bacillus tuberculosis (TB).

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior to the first dose of study intervention.

          -  Has a known history of human immunodeficiency virus (HIV) infection. (Testing for HIV
             at screening is only required if mandated by local health authority.

          -  Has a known history of Hepatitis B virus (HBV) (defined as Hepatitis B surface antigen
             [HBsAg] reactive) or known active Hepatitis C virus (HCV) (defined as HCV ribonucleic
             acid [RNA] [qualitative] is detected) infection.

          -  Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 95 days
             after the last dose of study intervention.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Progression-free Survival (PFS) per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Time Frame:Up to approximately 47 months
Safety Issue:
Description:PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review will be presented

Secondary Outcome Measures

Measure:Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Time Frame:Up to approximately 47 months
Safety Issue:
Description:ORR is defined as the percentage of participants who have a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented.
Measure:Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Time Frame:Up to approximately 47 months
Safety Issue:
Description:For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR as assessed by blinded independent central review will be presented.
Measure:Number of Participants Who Experience One or More Adverse Events (AEs)
Time Frame:Up to approximately 47 months
Safety Issue:
Description:An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Measure:Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
Time Frame:Up to approximately 47 months
Safety Issue:
Description:An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants who discontinue study treatment due to an AE will be presented.
Measure:Time to Deterioration in Health-Related Quality-of-Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 29 and 30 Score
Time Frame:Up to approximately 47 months
Safety Issue:
Description:Time to Deterioration (TTD) is defined as the time from baseline to the first onset of a ≥10-point negative change (decrease) from baseline in global health status (Item 29) & quality of life (Item 30) combined score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in global health status and quality of life combined score, will be presented. A longer TTD indicates a better outcome.
Measure:Time to Deterioration in Physical Functioning Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 1- 5 Score
Time Frame:Up to approximately 47 months
Safety Issue:
Description:TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in physical functioning (EORTC QLQ-C30 Items 1-5) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in physical functioning score, will be presented.
Measure:Time to Deterioration in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) Items 1-9 Score
Time Frame:Up to approximately 47 months
Safety Issue:
Description:The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer over the previous 7 days. Responses are scored on a 5-point scale (0=Not at all to 4=Very much) and summed to generate an index symptom score. These scores can range from 0 to 36, with a higher score indicating more favorable kidney cancer symptom status.
Measure:Change From Baseline in Health-Related Quality-of-Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 29 and 30 Score
Time Frame:Baseline (Day 1) and up to approximately 47 months
Safety Issue:
Description:The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses for global health status (Item 29) & quality of life (Item 30) are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 scores will be presented.
Measure:Change From Baseline in Physical Functioning Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 1- 5 Score
Time Frame:Baseline (Day 1) and up to approximately 47 months
Safety Issue:
Description:The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score will be presented.
Measure:Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) Items 1-9 Score
Time Frame:Baseline (Day 1) and up to approximately 47 months
Safety Issue:
Description:The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer over the previous 7 days. Responses are scored on a 5-point scale (0=Not at all to 4=Very much) and summed to generate an index symptom score. These scores can range from 0 to 36, with a higher score indicating more favorable kidney cancer symptom status.
Measure:Change from Baseline in European Quality of Life 5 Dimensions, 5-level Questionnaire (EuroQoL EQ-5D-5L) Health Utility Score
Time Frame:Baseline (Day 1) and up to approximately 47 months
Safety Issue:
Description:The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/ depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty, which are coded on a scale from 1 (no problems) to 5 (extreme problems). The participant is also asked to indicate his/her current health state by selecting the most appropriate level on a visual analog scale from 0 to 100, with 0 being the worst imaginable health state.

Details

Phase:Phase 3
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Merck Sharp & Dohme Corp.

Trial Keywords

  • Hypoxia inducible Factor (HIF)
  • Hypoxia inducible factor 1B (HIF-1B)
  • Hypoxia inducible factor 2 alpha (HIF-2 alpha)
  • Hypoxia inducible factor 2α (HIF-2α)
  • Renal Cell Carcinoma (RCC)
  • Kidney Cancer
  • PT-2977
  • PT2977
  • MK6482

Last Updated

December 20, 2019